|
|
Cell Genesys, Inc. - Comparative Business Analysis Snapshot
Business Description
Cell Genesys, Inc.. The Group's principal activities are researching, developing and commercializing novel biological therapies for patients with cancer. It currently has three product platforms: GVAX cancer vaccines, oncolytic virus therapies and cancer gene therapies. The Group conducts clinical trials in multiple types of cancer utilizing its GVAX cancer vaccines and oncolytic virus therapy product platforms. GVAX vaccines consist of irradiated tumor cells, genetically modified to secrete a hormone that stimulates the body's immune response to vaccines. Oncolytic virus therapies which employ genetically modified adenoviruses are engineered to selectively replicate in and kill cancer cells.
Competitor Analysis
This analysis compares Cell Genesys, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
